公开(公告)号：US20240336659A1

公开(公告)日：2024-10-10

申请号：US18287142

申请日：2022-04-15

Applicant: ONECUREGEN CO., LTD. ,  ICURE BNP CO., LTD. ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Kwan Young CHANG ,  Mi Sun WON ,  In Ah HWANG ,  Bo Kyung KIM ,  Kyeong Soo KIM ,  Seo Hee KANG ,  Song Yee HAN

IPC: C07K7/64 ,  A61K38/00 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08

CPC classification number: C07K7/64 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  A61K38/00 ,  C07K2319/10

Abstract: The present disclosure relates to a cell-penetrating peptide, an anticancer peptide, and a pharmaceutical composition for preventing or treating cancer including the same. The cell-penetrating peptide of the present disclosure can further improve a cancer cell growth inhibitory effect of anticancer peptides, especially cancer therapeutic peptides with improved anticancer activity by cyclic structures, and thus can be effectively applied to the prevention or treatment of various cancers.

公开(公告)号：US20240376165A1

公开(公告)日：2024-11-14

申请号：US17915085

申请日：2021-03-22

Applicant: ONECUREGEN CO., LTD.

Inventor： Mi Sun WON ,  Bo Kyung KIM ,  Joo-Young IM ,  Da Mi KIM

IPC: C07K14/47 ,  A61K38/00 ,  A61P35/00

Abstract: A peptide fragment for treatment of cancer, a variant thereof, and a use thereof. A peptide fragment of VGLL1 and/or a variant thereof inhibits the proliferation and invasion of cancer cells, thereby exhibiting an excellent effect on the prevention and treatment of cancer.

公开(公告)号：US20230219894A1

公开(公告)日：2023-07-13

申请号：US17794810

申请日：2020-11-16

Applicant: ONECUREGEN CO., LTD.

Inventor： Kyeong LEE ,  Mi Sun WON ,  Hyun-Seung BAN ,  Min Kyoung KIM ,  Bo-Kyung KIM

IPC: C07D217/06 ,  A61P35/00

CPC classification number: C07D217/06 ,  A61P35/00

Abstract: The present invention relates to: a disubstituted adamantyl derivative or a pharmaceutically acceptable salt thereof, and an anticancer pharmaceutical composition and a kit containing same as an active ingredient. The disubstituted adamantyl derivative according to the present invention suppresses the growth of cancer cells by targeting mitochondria ETC complex I and damaging the metabolism of cancer cells, and thus can be useful as an anticancer pharmaceutical composition that is a powerful therapeutic agent for cancer dependent on oxidative phosphorylation for producing ATP.